Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium

Arthritis and Rheumatism

Volumn 52, Issue 8, 2005, Pages 2331-2342

  Patterson, Angela M ^a,b   Gardner, Lucy ^b   Shaw, Jennifer ^b   David, Guido ^c   Loreau, Emilie ^d   Aguilar, Luc ^d   Ashton, Brian A ^b,e   Middleton, Jim ^b,e  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Prologue Biotech   (France)

^e KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL; GLYPICAN; GLYPICAN 1; GLYPICAN 3; GLYPICAN 4; HEPARIN LYASE; INTERLEUKIN 8; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; PROTEOHEPARAN SULFATE; SYNDECAN 1; SYNDECAN 2; SYNDECAN 3; SYNDECAN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CLINICAL ARTICLE; ENDOTHELIUM CELL; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BINDING SITES; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; FEMALE; HEPARITIN SULFATE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; MALE; MEMBRANE GLYCOPROTEINS; MICROCIRCULATION; MIDDLE AGED; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNDECAN-3; SYNOVIAL MEMBRANE;

EID: 23644441335     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21222     Document Type: Article

References (70)

1. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991;60:443-75 .
2. Esko JD, Lindahl U. Molecular diversity of heparan sulphate. J Clin Invest 2001;108:169-73.
3. Bernfield M, Gotte M, Park PE, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77.
4. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992;8:365-93.
5. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997;327:1-16.
6. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 2003;4:926-37.
7. Tumova S, Woods A, Couchman JR. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 2000;32:269-88.
8. Rapraeger AC. Syndecan-regulated receptor signaling. J Cell Biol 2000;149:995-8.
9. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001;11:19R-23R.
10. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998;67:609-52.
11. Halfter W, Dong S, Schurer B, Cole GJ. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 1998;273:25404-12.
12. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357-61.
13. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002;100:3853-60.
14. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38:12959-68.
15. Goger B, Halden Y, Rek A, Halden Y, Rek A, Mosl R, et al. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric intcrleukin-8: a model for chemokinc regulation at inflammatory sites. Biochemistry 2002;41:1640-6.
16. Halden Y, Rek A, Atzenhofer W, Szilak L, Wabnig A, Kungl AJ. Interleukin-8 binds to syndecan-2 on human endothelial cells. Biochem J 2004;377:533-8.
17. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994;4:394-400.
18. Luster AD, Greenberg SH, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995;182:219-31.
19. Stringer SE, Gallagher JT. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem 1997;272: 20508-14.
20. Spillman D, Witt D, Lindahl U. Defining the interleukin-8 binding domain of heparan sulfate. J Biol Chem 1998;273:15487-93.
21. Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, et al. Stromal cell-derived factor-1α associates with heparan sulfates through the first β-strand of the chemokine. J Biol Chem 1999;274:23916-25.
22. Stringer SE, Forster MJ, Mulloy B, Bishop CR, Graham GJ, Gallagher JT. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1α. Blood 2002;100: 1543-50.
23. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003;15:15-21.
24. Patterson AM, Schmutz C, Davis S, Gardner L, Ashton BA, Middleton J. Differential binding of chemokines to macrophages and neutrophils in the human inflamed synovium. Arthritis Res 2002;4:209-14.
25. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE. Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res 2001;3: 118-26.
26. Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol 1997; 182:106-14.
27. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model. J Exp Med 1997;186:131-7.
28. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997;57:117-20.
29. Endo H, Akahoshi T, Nishimura A, Tonegawa M, Takagishi K, Kashiwazaki S, et al. Experimental arthritis induced by continuous infusion of IL-8 into rabbit knee joints. Clin Exp Immunol 1994;96:31-5.
30. Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A. Binding to heparan sulphate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci U S A 1993;90: 7158-62.
31. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997;91:385-95.
32. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 2003;100:1885-90.
33. Tanaka Y, Fujii K, Hubscher S, Aso M, Takazawa A, Saito K, et al. Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. Arthritis Rheum 1998;41:1365-77.
34. Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 2003;170:2147-52.
35. Patel DD, Koopmann W, Imai T, Whichard LP, Yoshie O, Krangel MS. Chemokines have diverse abilities to form solid phase gradients. Clin Immunol 2001;99:43-52.
36. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997;36:13570-8.
37. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002;111:635-46.
38. Gotte M. Syndecans in inflammation. FASEB J 2003;17:575-91.
39. Kirkham B, Potek I, Lee CS. Intraarticular variability of synovial membrane histology, immunohistology and cytokine mRNA expression in patients with rheumatoid arthritis. J Rheumatol 1999; 26:777-84.
40. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
41. Patterson AM, Siddall H, Chamberlain G, Gardner L, Middleton J. Expression of the Duffy antigen/receptor for chemokines (DARC) by the inflamed synovial endothelium. J Pathol 2002;197: 108-16.
42. Brunner G, Gabrilove J, Rifkin DB, Wilson EL. Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 1991;114: 1275-83.
43. Wharton J, Walsh DA. Autoradiography of peptide receptors. Methods Mol Biol 1999;106:99-118.
44. Roskams T, de Vos R, David G, van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-7.
45. Lacorre DA, Baekkevold ES, Garrido I, Brandtzaeg P, Haraldsen G, Amalric F, et al. Plasticity of endothelial cells; rapid dedifferentiation of freshly isolated high endothelial venule (HEV) endothelial cells outside the lymphoid tissue microenvironment. Blood 2004;103:4164-72.
46. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-56.
47. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
48. Linhardt RJ, Turnbull JE, Wang HM, Loganathan D, Gallagher JT. Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 1990;29:2611-7.
49. Lundqvist K, Schmidtchen A. Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers. Br J Dermatol 2001;144:254-9.
50. Pfander D, Swoboda B, Kirsch T. Expression of early and late differentiation markers (proliferating cell nuclear antigen, syndecan-3, annexin VI, and alkaline phosphatase) by human osteoarthritic chondrocytes. Am J Pathol 2001;159:1777-83.
51. Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y, et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004; 100:1110-22.
52. Neumann S, Schuchardt K, Reske A, Reske A, Emmrich P, Paschke R. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules. Thyroid 2004;14:99-111.
53. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 2001;61:5562-9.
54. Szekanecz Z, Koch AE, Kunkel SL, Strieter RM. Cytokines in rheumatoid arthritis: potential targets for pharmacological intervention. Drugs Aging 1998;12:377-90.
55. Carter NM, Ali S, Kirby JA. Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. J Cell Sci 2003;116:3591-600.
56. Roskams T, de Vos R, David G, van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-7.
57. Roskams T, Rosenbaum J, de Vos R, David G, Desmet V. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases. Hepatology 1996;24:524-32.
58. Mertens G, Cassiman JJ, van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells: core protein characterization and antithrombin III binding properties. J Biol Chem 1992;267:20435-43.
59. Kojima T. Molecular biology of ryudocan, an endothelial heparan sulfate proteoglycan. Semin Thromb Hemost 2000;26:67-73.
60. Van Horssen J, Kleinnijenhuis J, Maass CN, Rensink AA, Otte-Holler I, David G. Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol Aging 2002;23:537-45.
61. Berndt C, Casaroli-Marano RP, Vilaro S, Reina M. Cloning and characterization of human syndecan-3. J Cell Biochem 2001;82: 246-59.
62. Kirsch T, Koyama E, Liu M, Golub EE, Pacifici M. Syndecan-3 is a selective regulator of chondrocyte proliferation. J Biol Chem 2002;277:42171-7.
63. Kosher RA. Syndecan-3 in limb skeletal development. Microsc Res Tech 1998;43:123-30.
64. Casar JC, Cabello-Verrugio C, Olguin H, Aldunate R, Inestrosa NC, Brandan E. Heparan sulfate proteoglycans are increased during skeletal muscle regeneration: requirement of syndecan-3 for successful fiber formation. J Cell Sci 2004;117:73-84.
65. Marshall LJ, Ramdin LS, Brooks T, DPhil PC, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003;171:2057-65.
66. Clasper S, Vekemans S, Fiore M, Plebanski M, Wordsworth P, David G, et al. Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J Biol Chem 1999;274:24113-23.
67. Fuki IV, Kuhn KM, Lomazov IR, Rothman VL, Tuszynski GP, Iozzo RV, et al. The syndecan family of proteoglycans: novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997;100:1611-22.
68. Fuki IV, Meyer ME, Williams KJ. Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts. Biochem J 2000;351:607-12.
69. Tkachenko E, Simons M. Clustering induces redistribution of syndecan-4 core protein into raft membrane domains. J Biol Chem 2002;277:19946-51.
70. Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von Andrian UH, et al. The CCR7 ligand elc (CCL19) is transcytoscd in high endothelial venules and mediates T cell recruitment. J Exp Med 2001;193:1105-12.